Aspire Biopharma Holdings, Inc.
No enriched coverage for $ASBP in the last 7 days.
No SEC Form 4 filings for $ASBP in the last 30 days.
See all $ASBP insider activity →Aspire Biopharma Holdings, Inc. (ASBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Aspire Biopharma Completes Acquisition of Dura Driver Control Systems , a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue ● Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve
Aspire Biopharma Holdings Inc. (NASDAQ:ASBP) said it completed a $30 million cash acquisition of Dura Driver Control Systems (DCS), gaining 100% ownership. Aspire also entered a $22.5 million senior secured revolving credit facility to fund the deal. DCS reported $209.5M audited 2025 revenue and $22.3M adjusted EBITDA. ASBP shares were down 0.39% to $7.70 premarket.
Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
Recent ASBP coverage spans corporate actions, market movers and mergers & acquisitions.
The filing signals a dilutive financing structure (convertible notes) with an investor option to convert upon an event of default, increasing near-term balance-sheet and dilution risk.
The DCS buyout is a diversification and scale step, funded with cash plus a new $22.5 million revolving credit facility.
A stated NDA filing plan is a forward-looking regulatory catalyst that can improve probability-weighted valuation.
Approval clears corporate governance steps needed for warrant exercises and related share issuance/terms adjustments.
The filing signals a completed/near-term M&A step that can change Aspire’s asset base, cash needs, and risk profile ahead of closing conditions.
alphai scores every news story that mentions ASBP with an AI model for sentiment and relevance, and aggregates insider trades from Aspire Biopharma Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aspire Biopharma Holdings, Inc. (ASBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Aspire Biopharma Completes Acquisition of Dura Driver Control Systems , a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue ● Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve
6 min readAspire Biopharma Holdings Inc. (NASDAQ:ASBP) said it completed a $30 million cash acquisition of Dura Driver Control Systems (DCS), gaining 100% ownership. Aspire also entered a $22.5 million senior secured revolving credit facility to fund the deal. DCS reported $209.5M audited 2025 revenue and $22.3M adjusted EBITDA. ASBP shares were down 0.39% to $7.70 premarket.
4 min readBiotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
6 min readAspire Biopharma Holdings, Inc. (ASBP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001847345 0001847345 2026-06-16 2026-06-16 0001847345 ASBP:CommonStockParValue0.0001PerShareMember 2026-06-16 2026-06-16 0001847345 ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STA
3 min readAspire Biopharma Holdings, Inc. (ASBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 PURCHASE AGREEMENT between FireFish TopCo, LLC and Aspire Biopharma Holdings, Inc. Dated as of June 10, 2026 TABLE OF CONTENTS Article I DEFINITIONS AND INTERPRETATIONS 1 Section 1.01. Definitions 1 Article II CLOSING 1 Section 2.01. Clos
6 min readBiotech stocks rose Monday as investors reacted to clinical and regulatory updates. Tango Therapeutics (TNGX) jumped 52.97% after initial Phase 1/2 pancreatic cancer data showed 90% 6-month PFS; Alvotech (ALVO) gained 19.77% as the FDA accepted its Entyvio interchangeable biosimilar AVT16; Zevra (ZVRA) rose 13.95% on an Orange Book listing for MIPLYFFA.
7 min readSciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.
6 min readAspire Biopharma (Nasdaq: ASBP) CEO Kraig Higginson sent a shareholder letter outlining plans for 2026. The board authorized a $5.0 million share repurchase after a preferred-stock private placement generated about $21.0 million net proceeds and the company regained Nasdaq equity compliance. Aspire said it plans to file an NDA for its high-dose sublingual aspirin via the 505(b)(2) pathway by end-2026. It also proposed acquiring Dura Driver Control Systems for $30 million cash; DCS reported 2025
4 min readAspire Biopharma Holdings (ASBP) will implement a 1-for-30 reverse stock split on May 11, 2026. This action will consolidate shares, reduce the total share count, and assign a new CUSIP number while retaining the existing ticker symbol. The company, operating in the biopharmaceutical sector, aims to manage its market position through this capital markets action.
2 min readAspire Biopharma Holdings, Inc. announced its Letter of Intent to acquire Dura Driver Control Systems (DCS), a leading global automotive supplier. The acquisition, valued at $30 million in cash, is expected to transform Aspire into a diversified, high-revenue enterprise, leveraging DCS's robust financial performance of over $200 million in revenue and $20 million in Adjusted EBITDA for FY2025. DCS specializes in automotive driver control systems with a strong patent portfolio and global manufacturing presence.
4 min read
